Phenylalanine and UVA light for the treatment of vitiligo.
The administration of phenylalanine (Phe) combined with UVA exposure was found to be effective in vitiligo. Phe is an amino acid which constitutes part of the daily dietary protein, and when orally administered in a dose of 50 mg/kg body weight, it results in an elevated plasma level. Since peak concentrations of Phe in the blood are reached between 30 and 45 min after ingestion, UVA exposure was administered at this time. After 4 months (32 treatments) reasonable repigmentation preferentially occurred in the skin area of subcutaneous fat (adipose tissue). Apart from the repigmentation of hypo-pigmented macules, vitiligo patients can tolerate more sun than usual, especially at the vitiliginous lesion, and they experience no sunburn as a result of Phe-UVA therapy. Normal skin also tans very well.
D000293:Adolescent; D000328:Adult; D002986:Clinical Trials as Topic; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male; D008875:Middle Aged; D010649:Phenylalanine / Q000097:blood / Q000627:therapeutic use*; D013472:Sunlight; D014443:Tyrosine / Q000097:blood; D014467:Ultraviolet Therapy; D014820:Vitiligo / Q000188:drug therapy / Q000628:therapy*
D014443:Tyrosine; D010649:Phenylalanine